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Idiopathic pulmonary fibrosis (IPF) is characterized by progressive deposition of extracellular
matrix, worsening dyspnea, and eventual mortality. Pathogenesis of IPF is poorly under-
stood and the role inflammation and activated leukocytes play in the disease process is
controversial. Previous studies demonstrated that activated leukocyte subsets character-
ize IPF patients. We sought to validate this observation in a well-defined cohort of 35 IPF
patients and to correlate the observed leukocyte phenotypes with robust parameters of dis-
ease progression. We demonstrate that in univariate and multivariate analyses, increases
in the CD14hi, CD16hi subset of monocytes measured at baseline correlated with disease
progression, with a threshold value >0.5% of the total peripheral blood mononuclear cells
being a significant predictor for worse outcome. In addition, several T cell subsets, including
CD25 expressing CD4 cells, and CXCR3 expressing CD4 and CD8 subsets correlated with
disease progression when found in increased percentages in the peripheral blood of IPF
patients when sampled at baseline. Somewhat surprising in comparison to previous litera-
ture, the CD4 T cells did not appear to have lost expression of the co-stimulatory molecule,
CD28, but the CD8 T cells did. Taken together, these results are consistent with the pres-
ence of an inflammatory process in IPF patients who eventually progress. However, when
longitudinal measurements of these same markers were examined, there was significant
heterogeneity of expression and these biomarkers did not necessarily remain elevated in
IPF patients with progressive disease. We interpret this heterogeneity to suggest that IPF
patients experience episodic inflammatory events that once triggered, may lead to disease
progression. This longitudinal heterogeneity in biomarker analyses may explain why such
markers are not consistently measured in all IPF cohorts.
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a devastating disease of
unknown etiology. It is characterized by progressive deposition
of extracellular matrix proteins, dyspnea, and eventual mortal-
ity. The natural history of the disease is variable, with some
patients experiencing relative stability over time, and others expe-
riencing a more rapid decline in lung function. There is an
on-going debate about the pathogenesis of IPF. Many investi-
gators believe that the disease results from aberrant epithelial–
mesenchymal cell interactions (1, 2). However, there have also
been numerous studies suggesting a role for occult viral infec-
tions as co-factors for disease development or progression (3).
Furthermore, results of immunosuppressive therapies have been
mixed in patients with interstitial lung disease. For instance,
two studies have reported benefit (4, 5) while a more recent
clinical trial demonstrated that immunosuppressive therapy was
harmful to these patients (6). This last trial raised the possi-
bility that at least some immune functions may be protective
in IPF.
Several past studies have sought to identify a phenotype of
circulating leukocytes that correlate with disease progression in
IPF. Most notably, previous studies have suggested CD4 T cells
in IPF patients display reduced levels of CD28, suggesting persis-
tent antigen activation and perhaps clonal exhaustion of these T
helper cells (7). Other studies have shown increased levels of MHC
class II and CD40 ligand (CD154) on CD4 cells in IPF patients
(8) and these same studies showed evidence of T cell recep-
tor Vβ oligoclonal expansion, again suggesting antigen-specific
expansion. These data are further supported by recent gene array
analysis of peripheral blood mononuclear cells in IPF and con-
trol patients. These genetic studies demonstrated that IPF patients
were characterized by a gene expression profile consistent with T
cell activation, including enhanced expression of CD28, inducible
T cell co-stimulator (ICOS), lymphocyte-specific protein tyrosine
kinase (LCK), and IL-2-inducible kinase (ITK), which are all T
cell co-stimulatory molecules (9). Past studies have also looked at
CD25 expressing T cells. CD25 is the IL-2 receptor and this pro-
tein is upregulated on both activated T cells and on T regulatory
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(Treg) cells. While two studies have found elevated levels of Tregs in
IPF patients (10, 11), two other studies have had opposite results
(12, 13). However, in the study by Kotsianidis et al., the func-
tion of the Tregs in IPF patients was found to be impaired. Taken
together, these data suggest that IPF patients are characterized by
pro-inflammatory and activated T cell phenotypes.
The ability of activated T cells to migrate into tissues is
controlled by chemokine receptors. Additionally, the chemokine
receptor profile correlates with the nature of the T cell activation.
The expression of CXCR3 on lymphocytes is believed to correlate
with Th1 responses while the expression of CCR4 is believed to
correlate with Th2 responses (14). A previous study looked at
the ratio of CXCR3 to CCR4 expressing lymphocytes in the lung
tissue of patients diagnosed with IPF vs. non-specific interstitial
pneumonitis (NSIP) and found that NSIP patients, which have a
better prognosis than IPF patients had a ratio of CXCR3>CCR4,
whereas IPF patients had a ratio that was approximately even (15).
These data suggested that the T cell activation in IPF patients is
likely skewed toward a Th2 response. Not surprisingly, the Th2
cytokines IL-4 and IL-13 are well known to promote fibrogenesis
in both animal models and human studies (16, 17).
Finally, there has been growing interest in phenotypes of cir-
culating monocytes in homeostasis and disease. In the mouse,
a population of Ly6Chi, Gr-1+ monocytes have been charac-
terized, which express high levels of CCR2, but low levels of
CX3CR1 (the fractalkine receptor). These cells are believed to
be inflammatory monocytes with increased phagocytic capac-
ity, lower cytokine expression, and a tendency to make IL-10 in
response to lipopolysaccharide (LPS) stimulation (18, 19). Ly6Chi
monocytes can facilitate alternative activation of macrophages
during fibrogenesis and depletion of this subset in mice can limit
lung collagen deposition (20). In human beings, this population
is characterized as CD14hi, CD16lo. In contrast, the murine pop-
ulation, which is characterized as Ly6Clo, Gr-1− is characterized
by high expression of CX3CR1, low CCR2 and this population of
cells is considered pro-inflammatory because they secrete TNFα
and IL-1 in response to bacterial LPS (18, 19, 21). This population
can also promote fibrosis as it has been shown to express vascular
endothelial growth factor, to promote myofibroblast differentia-
tion, and to increase collagen deposition (22). This population is
CD14hi CD16hi in human beings. Recent studies have shed light
on the role that various monocyte populations may play in the
pathogenesis of lung fibrosis by showing that circulating mono-
cytes can be a source of profibrotic matricellular proteins (23, 24)
and alternative activation of monocytes has been linked previously
to IPF (20, 23) and experimental lung fibrosis (25, 26).
The “correlating outcomes with biochemical markers to esti-
mate time-progression in IPF” (COMET) study was a longitudinal
observational study undertaken to assess whether readily accessi-
ble biomarkers could be identified that correlated with disease
progression. In this study, a cohort of 35 IPF patients had periph-
eral blood collected for immunophenotyping analysis. We chose
to examine T cell and monocyte compartments based on the lit-
erature described above to determine whether we could validate
any of these measures as markers of disease progression. Overall,
our results suggest that activated T cell and monocyte phenotypes
characterize progressive IPF.
MATERIALS AND METHODS
PATIENT ENROLLMENT
The COMET study was a multi-center, observational cohort
study of well-defined IPF patients followed prospectively at 16-
week intervals up to 80 weeks (www.clinicaltrials.gov, clinical
trial ID no. NCT01071707). Patients were diagnosed as hav-
ing IPF on the basis of characteristic CT scans or UIP pathol-
ogy confirmed by lung biopsy. All subjects underwent baseline
assessment, including demographics, patient-reported descrip-
tors, spirometry, diffusing capacity of the lung for CO (DLco), 6-
min walk testing (6MWT), and high-resolution computed tomog-
raphy. Patients were allowed to remain on current treatments.
The primary outcome (combined endpoint) was progression-
free (PF) survival as determined by the time until any of
the following: death, acute exacerbation of IPF, lung trans-
plant, or relative change in forced vital capacity (FVC, liters) of
≥10% or DLCO (ml min−1 mmHg−1) of 15%. Each site received
local Institutional Review Board approval. Two previous stud-
ies have reported on data collected from the COMET cohort
(24, 27).
SAMPLE PREPARATION AND FLOW CYTOMETRY CHARACTERIZATION
Peripheral blood was collected in EDTA-containing vacutainers at
study centers and samples were shipped by overnight mail using
cold packs to the University of Michigan. Whole blood was cen-
trifuged at 2500 rpm for 10 min and plasma was collected. Blood
cells were diluted in sterile saline and subjected to centrifugation
on Ficoll-hypaque to obtain the PBMC fraction. Cells were washed,
counted, and stained for flow cytometry using the following para-
meters. Cells were stained at 1.0× 106/well with either parameter
antibodies or IgG controls.
Parameter 1
APC Mouse anti-Human CD4 (BD Biosciences), FITC Mouse
Anti-Human CD8 (BD), PE Mouse Anti-Human CD28 (BD),
V450 Mouse Anti-Human CD194 (CCR4) (BD), Alexa Fluor 700
Mouse anti-Human CD183 (CXCR3) (BD), and PerCP-Cy5.5
Mouse anti-Human CD19 (BD).
Parameter 2
APC Mouse anti-Human CD4 (BD), FITC mouse anti-Human
HLA-DR (class II) (BD), PE mouse Anti-Human CD154 (BD),
and PerCp-Cy 5.5 mouse Anti-Human CD25 (BD).
Parameter 3
PE-Cy7 Mouse anti-Human CD14 (BD), PE Mouse Anti-Human
CD16 (BD), APC Rat anti-human TLR-9 (BD), FITC Mouse
Anti-Human CD64 (BD), APC Cy7 anti-Human CD206 (Biole-
gend, San Diego, CA, USA), and PerCP-Cy5.5 anti-Human CD192
(CCR2) (Biolegend).
Parameter 4
PE-Cy7 Mouse anti-Human CD14 (BD), APC Cy7 anti-Human
CD206 (Biolegend, San Diego, CA, USA). Following stain-
ing cells underwent further intra-cellular staining as described
by BD biosciences cytofix/cytoperm intra-cellular staining kit
for APC Rat anti-human TLR-9 (BD), and FITC anti-Human
Fractalkine/CX3CL1 (R&D systems, Minneapolis, MN, USA).
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Table 1 | Demographics, pulmonary function, and biomarker levels for patients stratified on the basis of disease progression.
Non-progressors Progressors
Parameters of interest n Mean SD Range n Mean SD Range p-Value
Age 9 65.7 7.9 53.0–75.0 22 64.8 8.9 44.0–78.0 0.84
DLCO 9 45.8 14.6 16.4–64.7 22 42.9 12.3 22.6–69.7 0.27
FVC 9 72.2 13.9 51.4–83.8 22 70.9 15.0 42.4–97.9 0.81
FEV1 9 77.2 19.3 53.4–98.1 22 73.9 15.9 44.1–107.4 0.84
Male 9 5 (55.6%) 22 13 (59.1%) 0.99
Past smoker 9 4 (44.4%) 22 14 (63.6%) 0.43
Desaturation 9 1 (11.1%) 22 12 (54.5%) 0.045*
History of gastroesophageal reflux disease 9 4 (44.4%) 22 13 (59.1%) 0.69
MONOCYTE PHENOTYPING
CD14 3 3.5 0.7 2.7–3.9 10 19.3 21.2 1.2–65.6 0.15
CD14 CD206 5 1.3 0.8 0.3–2.5 14 2.7 2.5 0.5–9.9 0.29
CD14 TLR9 5 4.9 7.5 0.3–17.8 5 2.5 1.5 0.1–4.2 0.99
CD14 fractalkine 5 0.5 0.3 0.1–0.8 5 2.1 3.3 0.1–7.9 0.40
C14hi CD16lo 9 2.8 1.5 0.1–5.0 22 3.5 2.2 0.7–7.6 0.65
CD14hi CD16lo CD64 9 2.7 1.5 0.02–4.4 22 3.4 2.2 0.2–7.6 0.68
CD14h CD16lo CCR2 9 2.2 1.7 0.01–4.8 22 3.3 2.1 0.4–7.3 0.27
CD14hi CD16hi 7 1.8 3.7 0.07–10.2 22 2.5 8.2 0.03–39.3 0.52
CD14hi CD16hi CD64 7 1.7 3.7 0.05–10.1 22 2.4 8.2 0.03–39.3 0.59
CD14hi CD16hi CCR2 7 1.7 3.7 0.002–10.2 22 2.4 8.3 0.03–39.3 0.63
CD4 PHENOTYPING
CD4 9 6.9 3.0 3.8–12.4 22 8.4 3.9 1.0–18.1 0.29
CD4 CD28hi 9 5.3 1.8 3.4–8.7 22 6.0 4.5 0.1–17.6 0.62
CD4 CD28lo 9 1.5 2.1 0.06–5.5 22 2.4 3.6 0.04–13.8 0.59
CD4 CD25 9 0.3 0.2 0.09–0.7 22 1.55 1.6 0.01–6.6 0.052
CD4 MHC class II 9 0.5 0.4 0.01–0.49 22 1.65 2.3 0.01–3.94 0.14
CD4 CD154 9 0.19 0.16 0.01–0.5 22 0.65 0.89 0.01–3.95 0.23
CD8 PHENOTYPING
CD8 9 4.5 6.9 0.5–22.1 22 3.3 2.0 1.1–8.1 0.33
CD8 CD28hi 9 1.3 1.4 0.3–4.6 22 1.0 0.8 0.1–2.6 0.98
CD8 CD28lo 9 3.2 5.6 0.2–17.5 22 2.3 1.9 0.3–6.8 0.31
CCR4 AND CXCR3 ANALYSES ONT CELLS
CCR4 5 7.4 12.3 0.06–28.9 18 7.0 5.8 0.2–19.8 0.33
CCR4 CD4 4 3.3 3.9 0.1–8.6 18 2.6 2.7 0.1–8.6 0.97
CCR4 CD8 5 0.5 0.7 0.01–1.8 18 1.1 0.8 0.01–2.8 0.17
CXCR3 5 5.9 6.6 0.9–16.6 18 14.1 12.4 1.2–46.2 0.11
CXCR3 CD4 5 2.1 2.1 0.3–4.6 18 5.7 4.2 0.05–12.3 0.15
CXCR3 CD8 5 0.5 0.4 0.2–1.2 18 2.9 6.0 0.1–26.5 0.03*
IgG controls. PE mouse IgG1(BD), APC Rat IgG2a (BD),
PerCp/Cy5.5 mouse IgG2b (Biolegend), Alexa Fluor 700 Mouse
IgG1 (BD), PE-Cy7 Mouse IgG2a (BD), V450 Mouse IgG1 (BD),
APC Cy7 Mouse IgG1 (Biolegend), FITC Mouse IgG2a (BD).
Following staining, cells were fixed with 2% paraformalde-
hyde and run on a BD Biosciences LSR II flow cytometer (San
Jose, CA, USA). Data were analyzed using Winlist 6.0 (Topsham,
ME, USA). Results are reported as the percent of the pheno-
type being analyzed in the total peripheral blood mononuclear
cell pool.
STATISTICAL ANALYSES
Demographics, pulmonary function, and biomarker levels are
compared between known progressors and non-progressors over
80 weeks of follow-up using Wilcoxon rank-sum tests for continu-
ous predictors and Fisher’s exact test for dichotomous predictors.
Additionally, boxplots were generated to provide a visual com-
parison between COMET progressors and non-progressors for
some biomarker levels tested. Four patients of the 35 patients
enrolled in this COMET study were excluded from this descrip-
tive analysis when classification by progressor status was unclear
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based on incomplete follow-up data. However, no exclusions of
this nature were made when conducting time-to-event analy-
ses described below. Univariate Cox proportional hazards mod-
els were fit to examine the association between each biomarker
level and reaching the combined endpoint. In order to compare
impact of biomarker levels in the various models, standardized
biomarker levels were calculated by subtracting mean levels and
subsequently dividing by the biomarker level SD. The standardiza-
tion allows us to interpret each hazard ratio (HR) in terms of a 1
SD increase in the biomarker level. In addition, optimized thresh-
old values for each biomarker were determined by the function
cox.main from the R AIM package and then subsequently assessed
for association with the combined endpoint. These analyses were
repeated adjusting for baseline characteristics including age, gen-
der, FVC%, DLCO%, desaturation<88% during 6MWT, history of
gastroesophageal reflux disease and smoking status. The index of
concordance is a measure of model fit based on the probability of
correctly predicting which patient will achieve the combined end-
point first when considering a pair of patients from the dataset.
This index was used to determine whether the original biomarker
level or the threshold representation achieved better model fit.
Longitudinal trajectories of biomarker levels over time are dis-
played by progressor vs. non-progressor status with a red dashed
line indicating thresholds identified previously using the R AIM
package as described above. Kaplan–Meier curves depict the PF
survival probability (combined endpoint) between subjects whose
biomarker level is above the identified threshold and those below
in a small time interval. The Kaplan–Meier curve assumes that
censoring is independent and can only occur at the right of the
time interval. All analyses are conducted in an exploratory manner
and therefore statistical significance as measured by p-values must
be taken in that context. That is, for every 20 statistical p-values
displayed in this manuscript, we would expect 1 comparison on
average to spuriously give a p-value of <0.05 due to the statis-
tical nature of exploratory analyses with multiple comparisons.
Significant p-values are indicated by asterisk in all tables.
RESULTS
BASELINE CLINICAL CHARACTERISTICS OF PROGRESSORS VS.
NON-PROGRESSORS
Of the 35 COMET patients analyzed in these studies, 22 met cri-
teria for progression and 9 remained stable. Four patients were
excluded from these analyses due to incomplete follow-up. Table 1
shows the baseline characteristics of COMET participants by dis-
ease progression status. This table also presents the mean values
for various leukocyte phenotypes arranged according to mono-
cyte, CD4 and CD8 phenotypes. In addition, levels of CXCR3 and
CCR4 staining on T cells are presented. There were no signifi-
cant differences in the age, DLCO, FVC, or FEV1 measurements
made at baseline between the two groups. As expected, there was
a slight male predominance in both groups. Although the pro-
gressive patients tended to have a higher history of smoking and
gastro esophageal reflux disease, these features did not reach sig-
nificance. The functional parameter that was significantly different
between these two groups was the tendency to desaturate during a
6MWT. 54.5% of the progressive patients desaturated during this
procedure whereas only 11.1% of the stable patients did so.
FIGURE 1 | Progressive IPF patients are characterized by higher
percentages of CD4 CD25+ and CD8 CXCR3+ cells. The box shows the
range of the data from 25th percentile to 75th percentile. The bar in the
middle of the box represents the median (50th percentile). The lower and
upper whiskers gives the range of the data with each whisker restricted to
1.5 times the interquartile range (which is defined as the upper quartile
minus the lower quartile) with circles indicating data outside of this whisker
range. (A) CD4 CD25 percentages are graphed; (B) CXCR3 CD8
percentages are graphed.
FIGURE 2 | Idiopathic pulmonary fibrosis patients have higher
percentages of CXCR3 than CCR4 expressing CD4T cells. Mean values
of each cell type were analyzed by unpairedT test adjusting for multiple
comparisons using the Holm–Sidak method. (A) graphs CD4 cells while
(B) graphs CD8 cells.
PROGRESSIVE IPF PATIENTS HAVE HIGHER PERCENTAGES OF CD4 CD25
AND CD8 CXCR3 EXPRESSING CELLS
Looking at the baseline biomarker characteristics, only two
analyses were significantly different or approached significance
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(p= 0.052) between progressors and non-progressors. There were
more CD4 CD25 and CXCR3 CD8 expressing T cells in the pro-
gressive cohort when compared to the stable IPF patients (Table 1).
Figure 1 shows boxplots graphically representing the percentages
of these cell types identified at baseline in the stable vs. progressive
IPF patients. On average, the progressive patients had fivefold more
CD4 CD25 cells. Similarly, the progressive patients had ~5.8-fold
higher percentages of CXCR3 expressing CD8 cells. The progres-
sive IPF patients have mean values of CXCR3 expressing CD4 and
CD8 T cells that are much greater (~2-fold or more) than their
mean values of CCR4 expressing cells (Table 1). This difference
reached significance for the CD4 subset (Figure 2). In contrast,
the ratios are more equivalent in the stable IPF patients.
INFLAMMATORY T CELL AND ACTIVATED MONOCYTES PREDICT IPF
PROGRESSION IN UNIVARIATE ANALYSES
The univariate associations between the percentages of each bio-
marker in the flow cytometry analyses of the peripheral blood
leukocytes and the likelihood of reaching the combined endpoint
for disease progression are shown in Table 2. A 1 SD increase
in the percentage of monocytes expressing high levels of both
CD14 and CD16 were found be to significantly associated with
reaching the combined endpoint with a hazard ratio (HR) 2.13
(95% CI 1.10–4.15), p= 0.026. In our analyses, essentially all of
these monocytes expressed both CD64, an Fc receptor upregulated
during cellular activation and CCR2, an inflammatory chemokine
receptor. Interestingly, the classic inflammatory macrophage sub-
set (CD14hi, CD16lo, CCR2+) was also associated with disease
progression. Patients with a 1 SD increase in the percentage of this
subset had a HR of 1.57 (95% CI 0.99–2.51) for meeting the com-
bined endpoint for disease progression and this result approached
significance (p= 0.056).
When looking at the percentage of CD4 cells that were noted in
the peripheral blood of IPF patients, progressive patients tended
to have more of every subtype (Table 1) although as mentioned
above, the only subset to approach significance was the CD4
CD25 subset. Univariate analyses showed a strong significance for
patients with a 1 SD increase in the number of CD4+CD25+ cells
experiencing disease progression, HR 2.13 (95% CI 1.37–3.33),
p= 0.0008.
RESULTS OF UNIVARIATE THRESHOLD-BASED-ANALYSES
DEMONSTRATE THAT INCREASED LEVELS OF MONOCYTE AND T CELL
SUBSETS PREDICT PROGRESSION
We next wanted to determine whether thresholds for each
biomarker could be established that could predict which patients
Table 2 | Univariate Cox model results based on standardized biomarker level values.
Parameters of interest n HR 95% CI p-Value Index of concordance
MONOCYTE PHENOTYPES
CD14 13 1.32 0.80–2.17 0.278 0.720
CD14 CD206 22 1.29 0.87–1.93 0.208 0.602
CD14 TLR9 12 0.76 0.24–2.34 0.627 0.395
CD14 fractalkine 12 1.91 0.73–4.99 0.185 0.605
C14hi CD16lo 35 1.43 0.89–2.29 0.141 0.591
CD14hi CD16lo CD64 35 1.43 0.89–2.32 0.142 0.589
CD14hi CD16lo CCR2 35 1.57 0.99–2.51 0.056 0.638
CD14hi CD16hi 33 2.13 1.10–4.15 0.026* 0.593
CD14hi CD16hi CD64 33 2.20 1.10–4.38 0.025* 0.584
CD14hi CD16hi CCR2 33 2.10 1.09–4.06 0.027* 0.584
CD4 PHENOTYPES
CD4 35 1.43 0.94–2.17 0.099 0.618
CD4 CD28hi 35 1.27 0.82–1.95 0.283 0.598
CD4 CD28lo 35 1.15 0.78–1.70 0.471 0.553
CD4 CD25 35 2.13 1.37–3.33 0.0008* 0.687
CD4 MHC class II 35 1.18 0.87–1.61 0.277 0.581
CD4 CD154 35 1.2 0.89–1.62 0.231 0.581
CD8 PHENOTYPES
CD8 35 1.00 0.71–1.42 0.981 0.654
CD8 CD28hi 35 1.04 0.72–1.52 0.821 0.600
CD8 CD28lo 35 1.00 0.70–1.43 0.982 0.370
CCR4 AND CXCR3 ANALYSES
CCR4 26 0.94 0.57–1.57 0.827 0.529
CCR4 CD4 25 0.93 0.58–1.48 0.753 0.511
CCR4 CD8 26 0.89 0.58–1.37 0.610 0.420
CXCR3 26 2.42 1.47–3.97 0.0005* 0.706
CXCR3 CD4 26 1.73 1.12–2.67 0.014* 0.662
CXCR3 CD8 26 33.72 4.21–270.32 0.001* 0.775
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would go on to progress. Results of univariate threshold-based
analyses of biomarker levels are shown in Table 3. Interestingly, in
this analysis, patients with CD14 monocyte percentages >4 had
a HR of 12.41 (95% CI 1.49–103.22), p= 0.02. Analyzing which
populations of these monocytes had the highest predictive value,
both inflammatory CD14hi CD16lo and CD14hi CD16hi subsets
were strongly correlated with progressive disease. Figure 3A shows
the Kaplan–Meier plots analyzing the probability of PF survival for
patients with inflammatory monocytes (CD14hi CD16lo CCR2+)
found at thresholds above and below 4.8% of the peripheral blood
pool. Similarly, Figure 3B shows the Kaplan–Meier plots analyz-
ing CD14hi, CD16hi, CD64+monocytes at thresholds below and
above 0.5% of the peripheral blood pool. Collectively, these data
show that patients with elevated percentages of these markers have
poor PF survival as judged by meeting the combined endpoint.
When looking at the T cell markers, higher percentages of CD8
cells and CXCR3 expressing T cells were all positively associated
with an increased risk of disease progression. In addition, lev-
els of CD4 CD25 cells above the threshold of 0.74% and levels
of CD4 CD28hi T cells above 8.7% predicted worse outcomes.
Figures 3C,D show the Kaplan–Meier plot showing the decreased
probability of PF survival for patients with CD4 CD25 expressing
cells below and above 0.74% and for patients with CXCR3 CD8
cells above and below 1.3%, respectively.
MULTIVARIATE ANALYSES CONFIRM INFLAMMATORY AND ACTIVATED
LEUKOCYTES PREDICT POOR OUTCOMES IN IPF PATIENTS
We next performed a series of multivariate analyses: Table 4
shows corresponding results when adjusted for age, gender, FVC%,
DLCO%, desaturation <88% during 6MWT, history of gastroe-
sophageal reflux disease and smoking status. Table 5 provides
threshold analyses that are adjusted for the factors listed above.
In multivariate analyses, our results demonstrated continued sig-
nificance for a change of 1 SD in the percentages of the CD14hi
CD16hi monocyte subset correlating with disease progression.
However,only the CD14hi,CD16hi,CD64 expressing subset main-
tained significance in the threshold analyses suggesting that per-
centages above 0.5% predict poor outcomes. This is also supported
by the Kaplan–Meir plots in Figure 3B. Although not signifi-
cant in the multivariate Cox-models, a threshold above which
all of the CD14hi CD16lo subsets could predict disease pro-
gression was noticeable in the multivariate analyses. Consistent
with the concept that IPF patients have activated lymphocyte
profiles, higher levels of CD4 cells (>10% of total peripheral
Table 3 | Univariate threshold-based analyses of biomarker levels and association between reaching the combined endpoint.
Parameters of interest n HR 95% CI p-Value Index of concordance
MONOCYTETHRESHOLDS
CD14>4 13 12.41 1.49–103.22 0.020* 0.740
CD14 CD206>1.8 22 2.72 0.93–7.96 0.068 0.620
CD14 TLR9>1.3 12 3.87 0.43–34.9 0.228 0.686
CD14 fractalkine>0.7 12 2.26 0.37–13.8 0.376 0.628
C14hi CD16lo>5 35 5.54 1.97–15.53 0.001* 0.620
CD14hi CD16lo CD64>4.6 35 2.86 1.15–7.12 0.024* 0.623
CD14hi CD16lo CCR2>4.8 35 5.54 1.97–15.53 0.001* 0.620
CD14hi CD16hi>0.5 33 2.45 1.01–5.94 0.047* 0.627
CD14hi CD16hi CD64>0.5 33 2.77 1.17–6.55 0.020* 0.648
CD14hi CD16hi CCR2>0.2 33 0.85 0.36–2.02 0.717 0.485
CD4THRESHOLDS
CD4>10 35 2.08 0.84–5.12 0.112 0.603
CD4 CD28hi>8.7 35 3.92 1.55–9.92 0.004* 0.621
CD4 CD28lo>4.7 35 0.92 0.31–2.73 0.883 0.521
CD4 CD25>0.74 35 4.73 1.86–12.05 0.001* 0.678
CD4 MHC class II>0.11 35 0.65 0.19–2.22 0.494 0.526
CD4 CD154>0.03 35 2.65 0.3–19.76 0.342 0.528
CD8THRESHOLDS
CD8>2 35 2.68 0.98–7.29 0.054 0.633
CD8 CD28hi>1.8 35 2.63 0.95–7.31 0.063 0.592
CD8 CD28lo>1.9 35 2.43 1.03–5.74 0.043* 0.605
CCR4 AND CXCR3THRESHOLDS
CCR4>6 26 0.66 0.27–1.65 0.376 0.584
CCR4 CD4>7.6 25 0.95 0.21–4.19 0.942 0.526
CCR4 CD8>2.7 26 0.30 0.04–2.25 0.242 0.546
CXCR3>7.5 26 2.58 1.00–6.68 0.050 0.616
CXCR3 CD4>10.3 26 2.98 0.96–9.3 0.060 0.578
CXCR3 CD8>1.3 26 17.12 3.49–83.96 0.00046* 0.712
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FIGURE 3 | Kaplan–Meier plots show decreased probability of
progression-free (PF) survival for patients with elevated
percentages ofT cell and monocyte subsets above identified
thresholds. Patients with elevated percentages of (A) CD14hi
CD16lo CCR2+ monocytes, (B) CD14hi,CD16hi, CD64+
monocytes, (C) CD4 CD25 T cells, and (D) CXCR3 CD8 T cells above
the indicated thresholds identified inTable 3 show worse probability
of PF survival.
blood) or increases in CD8 cells >2% in the peripheral blood
marked patients at risk of functional decline. In the threshold
analyses, it appears the T cells maintaining high levels of CD28
have the highest predictive value. The associations with higher
CXCR3 expressing CD8 cells correlating with disease progression
were maintained in every analysis. This is also consistent with the
Kaplan–Meier analyses in Figure 3D.
LONGITUDINAL ANALYSES OF SIGNIFICANT BIOMARKERS ARE HIGHLY
VARIABLE
Across the univariate, multivariate, and threshold analyses, per-
centages of both CD4 CD25 and CD8 CXCR3 expressing T cells
measured at baseline predicted IPF disease progression and worse
survival (Figures 3C,D). To determine whether elevations in these
cellular phenotypes were stable across the 80-week observation
period, longitudinal spaghetti plots were generated. Figure 4
demonstrates that percentages of these cellular phenotypes were
variable with time. As expected, levels detected in non-progressive
patients were generally below the threshold limit. However, in the
progressive patients, elevations in the percentages of these cell
types were not maintained over time. To determine whether the
monocyte phenotypes associated with disease progression in our
threshold analyses also showed a similar variation, we performed
a similar longitudinal analysis for the CD14 hi CD16hi CD64
and the CD14hi CD16lo CD64 expressing monocytes. Again, as
expected, the non-progressive patients generally had percentages
that were below the threshold limit at all time points (Figure 5).
However, like the T cell analyses, the progressive IPF patients
demonstrated highly variable percentages of the cell types over
time.
DISCUSSION
This study was undertaken to determine whether activated leuko-
cyte phenotypes at baseline could predict which IPF patients were
at risk of disease progression. We chose to analyze T cell mark-
ers based on three previous studies that had indicated activated
T cells characterize IPF patients (7–9). In two of these studies,
the activated T cell phenotypes were associated with worse out-
comes (7, 9). Furthermore, the study by Gilani et al. suggested
that IPF patients were characterized by low levels of CD28 on
CD4 T cells, results that the authors interpreted to indicate per-
sistent antigen activation. Based on this, we were surprised that in
our multivariate Cox-models in Table 4, it was the CD4 CD28hi
population of T cells that correlated with progression in our
study. While loss of CD28 can be a marker of clonal exhaus-
tion, upregulation of CD25, MHC class II, and CD154 are also
indications of T cell activation. As we did note that elevated
percentages of CD4 CD25 (in all analyses) correlated with dis-
ease progression, and CD4 MHC class II expressing CD4 cells
approached significance in multivariate analyses, we believe that
the progressive IPF patients are characterized by activated T cells
measured at baseline. Figure 3C highlights the rapid probabil-
ity of decline in PF survival noted in patients with levels of CD4
CD25 expressing T cells over the 0.74% threshold in peripheral
blood. CD25 can also be a marker of regulatory T cells as well
as activated T cells. Unfortunately, our analyses did not include
assessment of FoxP3, which would have more definitively differ-
entiated these two possibilities. It is not clear why our results
differ from those of Gilani et al., but one possibility is that our
patients were not as advanced in their disease process. In the
Gilani et al. study, the IPF patients were older and had worse
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Table 4 | Cox model results based on standardized biomarker level values adjusted for age, gender, dlco10%, fvc10%, desaturation,
gastroesophageal reflux disease and smoke status.
Parameters of interest n HR 95% CI p-Value Index of concordance
MONOCYTE PHENOTYPES
CD14 13 6.51E-08 0.0017–44.49 0.219 0.973
CD14 CD206 22 0.95 0.47–1.90 0.875 0.801
CD14 TLR9 12 239.80 1.2e-11-4.8e15 0.726 1.000
CD14 fractalkine 12 0.44 5.5e-18-3.5e16 0.967 1.000
C14hi CD16lo 35 1.36 0.82–2.26 0.232 0.738
CD14hi CD16lo CD64 35 1.42 0.85–2.38 0.177 0.744
CD14hi CD16lo CCR2 35 1.52 0.91–2.56 0.112 0.746
CD14hi CD16hi 33 2.59 1.15–5.86 0.022* 0.730
CD14hi CD16hi CD64 33 2.67 1.17–6.06 0.019* 0.721
CD14hi CD16hi CCR2 33 2.67 1.17–6.11 0.020* 0.723
CD4 PHENOTYPES
CD4 35 1.66 0.99–2.78 0.053 0.764
CD4 CD28hi 35 1.77 1.08–2.88 0.022* 0.770
CD4 CD28lo 35 0.96 0.61–1.53 0.871 0.722
CD4 CD25 35 1.78 1.04–3.03 0.035* 0.758
CD4 MHC class II 35 0.99 0.67–1.47 0.096 0.728
CD4 CD154 35 1.06 0.71–1.57 0.785 0.734
CD8 PHENOTYPES
CD8 35 1.13 0.70–1.84 0.611 0.730
CD8 CD28hi 35 1.17 0.71–1.95 0.537 0.740
CD8 CD28lo 35 1.11 0.68–1.82 0.663 0.724
CCR4 AND CXCR3 PHENOTYPES
CCR4 26 0.64 0.33–1.26 0.201 0.730
CCR4 CD4 25 0.73 0.43–1.24 0.247 0.734
CCR4 CD8 26 0.76 0.40–1.44 0.400 0.734
CXCR3 26 2.14 1.18–3.90 0.012* 0.782
CXCR3 CD4 26 1.78 0.91–3.46 0.090 0.754
CXCR3 CD8 26 125.23 5.00–3133.5 0.003* 0.792
baseline lung function than in our cohort (7). Thus, it is pos-
sible that our cohort of IPF patients have not yet achieved the
levels of T cell clonal exhaustion noted in their study. Another
possibility is that expression levels in our cohort may have been
affected by the overnight shipment of samples from multiple cen-
ters rather than being carried out on the day of blood draw. Finally,
it is possible that the inherent heterogeneity of the measurement
of these markers when analyzed over time (as demonstrated in
Figure 4 for the CD4 CD25 fraction of cells) may explain such
discrepancies.
Further support for our interpretation that progressive IPF
patients are characterized by activated T cells comes from the
knowledge that the CXCR3 chemokine receptor is highly expressed
on activated T cells, and in particular T cells, which can migrate
into inflamed tissues such as rheumatoid synovium (28). However,
it is interesting to note that our findings of increased percent-
ages of CXCR3+CD8+ cells predicting disease progression in
IPF patients are at odds with a previous murine study and two
immunohistochemical studies of lung lymphocytes (15, 29, 30).
In the study by Jiang et al., CXCR3-deficient mice were shown
to have worse experimentally induced lung fibrosis (29). This
was associated with a failure to generate IFNγ in response to
bleomycin-injury. Furthermore, a previous study suggested that
CCR4 expression correlates with Th2 activation while CXCR3
expression correlates with Th1 cell activation and suggested that
IPF patients are characterized by relatively equal ratios of CXCR3
and CCR4 expressing T cells whereas NSIP patients who have bet-
ter prognoses are characterized by elevated expression levels of
CXCR3. (15). In our study, IPF progressors had higher ratios of
CXCR3 to CCR4 expression, suggesting Th1 activation. Further-
more, patients with levels of CXCR3 expressing CD8 T cells>1.3%
of the peripheral blood had rapid PF survival decline (Figure 3D).
The differences in our study and the previous study could be
explained by methodology. The previous study stained sections
of lung tissue while our results examined peripheral blood. It is
likely that the chemokine profiles of tissue-recruited lymphocytes
could be quite different. In support of this, Pignatti et al. con-
firmed that bronchoalveolar lavage cells from IPF patients had
lower levels of CXCR3 than CCR4 expressing T cells (30); how-
ever, these same differences were not noted in peripheral blood.
This highlights the tissue-specific differences in chemokine recep-
tors which seem to mark lung vs. circulating T cells. While it is not
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Table 5 |Threshold-based analyses of biomarker levels and association between reaching the combined endpoint adjusted for age, gender,
dlco10%, fvc10%, desaturation, gastroesophageal reflux disease, and smoke status.
Parameters of interest n HR 95% CI p-Value Index of concordance
ADJUSTED MONOCYTETHRESHOLDS
CD14>4 13 2689.73 2.57E-95–2.81E+101 0.945 0.893
CD14 CD206>1.8 22 0.61 0.07–5.4 0.659 0.786
CD14 TLR9>1.3 12 1.9e3 7.0e-42–5.2e47 0.885 1.000
CD14 fractalkine>0.7 12 1.8e5 0.00–Inf 0.988 1.000
C14hi CD16lo>5 35 13.93 2.86–67.91 0.001* 0.780
CD14hi CD16lo CD64>4.6 35 4.62 1.50–14.21 0.008* 0.778
CD14hi CD16lo CCR2>4.8 35 13.93 2.86–67.91 0.001* 0.780
CD14hi CD16hi>0.5 33 2.03 0.67–6.13 0.209 0.730
CD14hi CD16hi CD64>0.5 33 2.79 1.07–7.33 0.037* 0.746
CD14hi CD16hi CCR2>0.2 33 1.22 0.47–3.17 0.685 0.712
ADJUSTED CD4THRESHOLDS
CD4>10 35 3.63 1.13–11.69 0.031* 0.795
CD4 CD28hi>8.7 35 4.42 1.34–14.57 0.015* 0.762
CD4 CD28lo>4.7 35 0.59 0.18–1.92 0.378 0.732
CD4 CD25>0.74 35 3.13 1.17–8.39 0.023* 0.756
CD4 MHC class II>0.11 35 0.64 0.17–2.41 0.511 0.722
CD4 CD154>0.03 35 2.08 0.26–16.4 0.487 0.730
ADJUSTED CD8THRESHOLDS
CD8>2 35 3.35 1.09–10.28 0.035* 0.770
CD8 CD28hi>1.8 35 4.39 1.12–17.14 0.033* 0.760
CD8 CD28lo>1.9 35 2.17 0.81–5.82 0.125 0.742
ADJUSTED CCR4 AND CXCR3THRESHOLDS
CCR4>6 26 0.38 0.13–1.12 0.079 0.765
CCR4 CD4>7.6 25 0.53 0.09–3.18 0.488 0.726
CCR4 CD8>2.7 26 0.22 0.02–2.00 0.178 0.768
CXCR3>7.5 26 1.57 0.49–5.04 0.452 0.747
CXCR3 CD4>10.3 26 5.28 0.68–40.79 0.111 0.713
CXCR3 CD8>1.3 26 16.48 2.78–97.56 0.002* 0.826
clear why the association with circulating CXCR3 CD8 cells and
IPF disease outcome is so great in our cohort, we interpret the T
cell results overall to suggest that there is a strong inflammatory
response present at baseline in the patients who progress. The fact
that the activated T cell phenotypes do not persist longitudinally
(Figure 4) may suggest that we “caught” some IPF patients during
an episodic inflammatory event. Given the 80 weeks of follow-
up, we had the greatest power to detect progression in patients
who were experiencing this inflammatory event at week 0. It is
possible that elevations in any of these markers at later time points
in patients we classified as non-progressors may actually be pre-
dictive of their eventual decline, but because our analyses stopped
after 80 weeks, we had insufficient clinical data to make such a
determination.
Another interesting finding in our study was the observa-
tion that increases in CD14hi CD16hi expressing cells at baseline
correlated with disease progression in both univariate and mul-
tivariate analyses. As expected, this population largely expresses
not only CD64 but also CCR2. The murine equivalent of this
subset of monocytes has previously been suggested to promote
myofibroblast differentiation (22). While the association with
this subset of monocytes and disease progression was consis-
tent throughout all of our analyses, it should be noted that
this cohort of cells represents a relatively small fraction of
the total peripheral blood pool. Patients with CD14hi, CD16hi,
CD64+ cells above 0.5% of peripheral blood at baseline had
worse PF survival outcomes (Figure 3B), but these percent-
ages varied considerably over time (Figure 5). Certainly, the
paracrine factors secreted by such cells could have profound
impact on resident lung mesenchymal cells even if present in small
numbers.
It is interesting that in the univariate, multivariate, and thresh-
old analyses, percentages of CD14+CD206+ cells did not correlate
with disease progression. These data were surprising to us as
alternatively activated macrophages (defined by expression of
the CD206 mannose receptor or CD163 scavenger receptor) are
believed to be associated with IPF (20, 31). In mouse models,
depletion of the Ly6Chi population was shown to reduce the
degree of alternatively activated macrophages found in lung tissue
and their adoptive transfer could promote fibrosis even though the
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FIGURE 4 | Longitudinal analyses ofT cell phenotypes are highly
variable. The percentage of CD4 CD25 (A) or CD8 CXCR3 (B) expressing T
cells identified at longitudinal time points (weeks 0, 16, 32, 46, 64, and 80)
were graphed. The dotted red line indicates the threshold above which this
cell population was found to predict the patient reaching the combined
endpoint inTable 5. For both of these markers, univariate and multivariate
analyses of the percentages at baseline significantly separated
non-progressors from progressors. However, elevation of the marker at
baseline, did not predict stable elevation of the marker over time.
Ly6Chi monocytes were not found in the lung tissue. Extrapolating
to the human circumstance, this would suggest that the CD14hi
CD16lo population would correlate with development of the
CD206+ alternatively activated macrophages. While the univari-
ate analyses did show an increased hazard ratio (HR= 1.57) for
patients with increases in the CD14hi, CD16lo, CCR2+ cells, the
significance was not maintained in the multivariate analyses and
this may explain our inability to demonstrate an association with
alternatively activated monocytes in our relatively small cohort of
IPF patients.
In summary, our results are consistent with studies suggest-
ing that the presence of activated lymphocytes in the blood of
IPF patients. Patients who had elevated levels of CD4 CD25, CD8
CXCR3, and various subsets of both CD14hi CD16hi and CD14hi
CD16lo monocytes all demonstrated disease progression. The fact
that these biomarkers were not stably elevated over time, suggests
that IPF patients experience episodic inflammatory events (per-
haps driven by occult infections), which ultimately mark them
for disease progression. Our documentation of biomarker hetero-
geneity over time complicates the interpretation of these markers
for determining patient outcomes. Certainly, patients who display
such elevations may be appropriate for enrollment in therapeutic
trials, but clearly the absence of such markers at baseline does not
guarantee stability. Thus, it may be more appropriate to serially
monitor IPF patients for a panel of inflammatory and activated
leukocyte phenotypes in order to predict the likelihood that they
will progress following such an episode. In this regard, identi-
fying appropriate thresholds for triggering such declines will be
crucial, and will take a much larger study. Interestingly, a recent
FIGURE 5 | Longitudinal analyses of monocyte phenotypes are highly
variable. The percentage of CD14hi CD16hi CD64 (top) or CD14hi CD16lo
CD64 (bottom) expressing monocytes identified at longitudinal time points
(weeks 0, 16, 32, 46, 64, and 80) were graphed. The dotted red line
indicates the threshold above which this cell population was found to
predict the patient reaching the combined endpoint inTable 5.
study looking at longitudinal variability in circulating fibrocytes
in Hermansky–Pudlak patients with interstitial lung disease also
indicated episodic elevations over time, but found threshold lev-
els for the highest measurement ever that predicted mortality
(32). A caveat to the interpretation of our study is that we did
not protocolize the collection of information regarding infection,
on-going smoking status, or current treatments thus, some of
our observed variability may be related to unknown and non-
standardized therapeutics. We cannot determine whether any of
these factors influenced our measurements over time. It is also
interesting to speculate that IPF patients may decline because
they are not able to sufficiently activate their innate and adap-
tive leukocytes. While immunosuppressive therapy has shown
benefit in some interstitial lung diseases (4, 5), the results are
somewhat controversial because of the recent study, which found
that immunosuppressive agents do not benefit patients with IPF
(6). While there may be differences in the cohorts used in all
these studies, we believe, based on our current results that it is
interesting to speculate that immune stimulation may have some
benefit.
AUTHOR CONTRIBUTIONS
Collected samples: Fernando J. Martinez, MeiLan K. Han, and
Kevin R. Flaherty. Processed samples, performed flow cytome-
try: Bethany B. Moore and Chris Fry. Analyzed data and inter-
preted results: Bethany B. Moore, Yueren Zhou, Susan Murray,
Fernando J. Martinez, and Kevin R. Flaherty. Prepared manu-
script: Bethany B. Moore, Yueren Zhou, Susan Murray, and Kevin
R. Flaherty. Edited manuscript: Bethany B. Moore, MeiLan K. Han,
Yueren Zhou, Susan Murray, Fernando J. Martinez, and MeiLan K.
Han.
Frontiers in Medicine | Pulmonary Medicine December 2014 | Volume 1 | Article 56 | 10
Moore et al. Activated leukocytes in IPF
ACKNOWLEDGMENTS
The authors would like to thank the IPF patients in the COMET
trial for participating in research and are also indebted to the
COMET investigators at the participating sites for sample and
clinical data collection. COMET Investigators: Brown University,
Providence, RI, USA – Kevin Dushay (site PI), Jonathon Kurtis.
Cleveland Clinic Foundation, Cleveland, OH, USA – Jeffrey T
Chapman (site PI). Duke University – Kevin Anstrom (site PI).
National Jewish Health, Denver, CO, USA – Kevin K. Brown (site
PI), Gregory Cosgrove, Joshua Solomon, Jeffrey Swigris, Evans
Fernandez-Perez. Temple University, Philadelphia, PA, USA – Ger-
ard Criner (site PI), Francis Cordova, Namrata Patel, Thomas
Rogers. University of California Los Angeles, Los Angeles, CA,
USA – John Belperio (site PI). University of California, San Fran-
cisco, CA, USA – Talmadge E. King Jr. (site PI), Harold R. Collard.
University of Chicago, Chicago, IL, USA – Imre Noth (site PI),
Cathy Brown, Joe G. N. Garcia, D. Kyle Hogarth,Yong Huang,Yves
Lussier, Shwu-Fan Ma, Michael Wade. University of Michigan,Ann
Arbor, MI, USA – Fernando J. Martinez, Kevin R. Flaherty, Galen
B. Toews, Eric S. White (Principal Investigators), MeiLan K. Han,
Cory Hogaboam, Vibha Lama, Bethany B. Moore, Thomas Moore,
Susan Murray, Cathie Spino. Vanderbilt University, Nashville, TN,
USA – James E. Loyd (site PI).
REFERENCES
1. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic
cross-talk disorder. Respir Res (2002) 3:3. doi:10.1186/rr188
2. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of
the enigmatic idiopathic pulmonary fibrosis: an integral model. Am J Respir Crit
Care Med (2014) 189(10):1161–72. doi:10.1164/rccm.201312-2221PP
3. Naik PK, Moore BB. Viral infection and aging as cofactors for the develop-
ment of pulmonary fibrosis. Expert Rev Respir Med (2010) 4:759–71. doi:10.
1586/ers.10.73
4. Kondoh Y, Taniguchi H,Yokoi T, Nishiyama O, Ohishi T, Kato T, et al. Cyclophos-
phamide and low-dose prednisolone in idiopathic pulmonary fibrosis and
fibrosing nonspecific interstitial pneumonia. Eur Respir J (2005) 25:528–33.
doi:10.1183/09031936.05.00071004
5. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al.
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years
in scleroderma lung disease. Am J Respir Crit Care Med (2007) 176:1026–34.
doi:10.1164/rccm.200702-326OC
6. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, aza-
thioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012)
366:1968–77. doi:10.1056/NEJMoa1113354
7. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, et al. CD28
down-regulation on circulating CD4 T-cells is associated with poor prog-
noses of patients with idiopathic pulmonary fibrosis. PLoS One (2010) 5:e8959.
doi:10.1371/journal.pone.0008959
8. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski
JM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis.
J Immunol (2007) 179:2592–9. doi:10.4049/jimmunol.179.4.2592
9. Herazo-Maya JD, Noth I, Duncan SR, Kim S, Ma SF, Tseng GC, et al. Periph-
eral blood mononuclear cell gene expression profiles predict poor outcome in
idiopathic pulmonary fibrosis. Sci Transl Med (2013) 5:205ra136. doi:10.1126/
scitranslmed.3005964
10. Reilkoff RA, Peng H, Murray LA, Peng X, Russell T, Montgomery R, et al.
Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic
pulmonary fibrosis and are implicated in transforming growth factor-beta1-
induced pulmonary fibrosis. Am J Respir Crit Care Med (2013) 187:180–8.
doi:10.1164/rccm.201206-1109OC
11. Galati D,De Martino M,Trotta A,Rea G,Bruzzese D,Cicchitto G,et al. Peripheral
depletion of NK cells and imbalance of the Treg/Th17 axis in idiopathic pul-
monary fibrosis patients. Cytokine (2014) 66:119–26. doi:10.1016/j.cyto.2013.
12.003
12. Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropou-
los P, et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in
idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 179:1121–30.
doi:10.1164/rccm.200812-1936OC
13. Shimizu Y, Dobashi K, Endou K, Ono A,Yanagitani N, Utsugi M, et al. Decreased
interstitial FOXP3(+) lymphocytes in usual interstitial pneumonia with discrep-
ancy of CXCL12/CXCR4 axis. Int J Immunopathol Pharmacol (2010) 23:449–61.
14. Campbell JD, HayGlass KT. T cell chemokine receptor expression in human Th1-
and Th2-associated diseases. Arch Immunol Ther Exp (Warsz) (2000) 48:451–6.
15. Yoshinouchi T, Naniwa T, Shimizu S, Ohtsuki Y, Fujita J, Sato S, et al. Expres-
sion of chemokine receptors CXCR3 and CCR4 in lymphocytes of idio-
pathic nonspecific interstitial pneumonia. Respir Med (2007) 101:1258–64.
doi:10.1016/j.rmed.2006.10.019
16. Jakubzick C, Kunkel SL, Puri RK, Hogaboam CM. Therapeutic targeting of
IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol Res (2004)
30:339–49. doi:10.1385/IR:30:3:339
17. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol (2008)
214:199–210. doi:10.1002/path.2277
18. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two prin-
cipal subsets with distinct migratory properties. Immunity (2003) 19:71–82.
doi:10.1016/S1074-7613(03)00174-2
19. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, het-
erogeneity, and relationship with dendritic cells. Annu Rev Immunol (2009)
27:669–92. doi:10.1146/annurev.immunol.021908.132557
20. Gibbons MA, Mackinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-
Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic
macrophage regulation of lung fibrosis. Am J Respir Crit Care Med (2011)
184:569–81. doi:10.1164/rccm.201010-1719OC
21. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human periph-
eral blood monocyte subsets. J Leukoc Biol (2001) 69:11–20. Available from:
http://www.jleukbio.org/content/69/1/11.long
22. Landsman L, Varol C, Jung S. Distinct differentiation potential of blood mono-
cyte subsets in the lung. J Immunol (2007) 178:2000–7. doi:10.4049/jimmunol.
178.4.2000
23. Desai B, Mattson J, Paintal H, Nathan M, Shen F, Beaumont M, et al. Differen-
tial expression of monocyte/macrophage-selective markers in human idiopathic
pulmonary fibrosis. Exp Lung Res (2011) 37:227–38. doi:10.3109/01902148.
2010.538132
24. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al. Periostin
promotes fibrosis and predicts progression in patients with idiopathic pul-
monary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 303:L1046–56.
doi:10.1152/ajplung.00139.2012
25. Murray LA, Rosada R, Moreira AP, Joshi A, Kramer MS, Hesson DP, et al.
Serum amyloid P therapeutically attenuates murine bleomycin-induced pul-
monary fibrosis via its effects on macrophages. PLoS One (2010) 5:e9683.
doi:10.1371/journal.pone.0009683
26. Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, et al. TGF-
beta driven lung fibrosis is macrophage dependent and blocked by serum amy-
loid P. Int J Biochem Cell Biol (2011) 43:154–62. doi:10.1016/j.biocel.2010.10.013
27. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al. Lung micro-
biome and disease progression in idiopathic pulmonary fibrosis: an analysis
of the COMET study. Lancet Respir Med (2014) 2:548–56. doi:10.1016/S2213-
2600(14)70069-4
28. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, et al.
The chemokine receptors CXCR3 and CCR5 mark subsets of T cells asso-
ciated with certain inflammatory reactions. J Clin Invest (1998) 101:746–54.
doi:10.1172/JCI1422
29. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, et al. Regulation of pul-
monary fibrosis by chemokine receptor CXCR3. J Clin Invest (2004) 114:291–9.
doi:10.1172/JCI200416861
30. Pignatti P, Brunetti G, Moretto D, Yacoub MR, Fiori M, Balbi B, et al. Role of
the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am
J Respir Crit Care Med (2006) 173:310–7. doi:10.1164/rccm.200502-244OC
31. Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J, Luttmann W, et al. Alter-
natively activated alveolar macrophages in pulmonary fibrosis-mediator pro-
duction and intracellular signal transduction. Clin Immunol (2010) 137:89–101.
doi:10.1016/j.clim.2010.06.017
32. Trimble A, Gochuico BR, Markello TC, Fischer R, Gahl WA, Lee JK,
et al. Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak
www.frontiersin.org December 2014 | Volume 1 | Article 56 | 11
Moore et al. Activated leukocytes in IPF
syndrome. Am J Respir Crit Care Med (2014). doi:10.1164/rccm.201407-
1287OC
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 17 September 2014; accepted: 02 December 2014; published online: 22
December 2014.
Citation: Moore BB, Fry C, Zhou Y, Murray S, Han MK, Martinez FJ, Flaherty KR
and The COMET Investigators (2014) Inflammatory leukocyte phenotypes correlate
with disease progression in idiopathic pulmonary fibrosis. Front. Med. 1:56. doi:
10.3389/fmed.2014.00056
This article was submitted to Pulmonary Medicine, a section of the journal Frontiers in
Medicine.
Copyright © 2014 Moore, Fry, Zhou, Murray, Han, Martinez, Flaherty and The
COMET Investigators. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Medicine | Pulmonary Medicine December 2014 | Volume 1 | Article 56 | 12
